Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Pharmalot

Pharmalittle: Novo Nordisk plans thousands of layoffs; Will former Allergan CEO return as chairman?

By Ed Silverman

Drug prices
Pharmalot

Lundbeck agrees to pay $52 million to resolve probe into using charities to assist patients

By Ed Silverman

Pharmalot

What Trump pushback? Bayer takes hefty price hikes on two cancer drugs in just six months

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer’s Hospira unit has another recall problem; Carl Icahn buys Allergan stock

By Ed Silverman

U.S. Sen. Claire McCaskill
Pharmalot

McCaskill introduces a bill to force pharma to disclose payments to patient advocacy groups

By Ed Silverman

Pharmalot

Pharmalittle: Philippine official blames deaths on Sanofi dengue vaccine; Pfizer wants you to know it still invests in neuroscience

By Ed Silverman

Pharmalot

Swiss attorney general will not pursue bribery charges against Novartis for payments to Trump lawyer

By Ed Silverman

Pharmalot

A new cost-shifting maneuver is causing average net prices for drugs to fall

By Ed Silverman

Pharmalot

Allergan is urged to split CEO and chairman jobs by ‘disappointed’ hedge funds

By Ed Silverman

Pharmalot

Pharmalittle: Takeda shareholders call Shire deal ‘madness’; Mylan wins biosimilar approval in the U.S.

By Ed Silverman

Sanofi
Pharmalot

Sanofi is the latest drug maker to say average net prices fell last year

By Ed Silverman

Pharmalot

Pharmalittle: PBM mail order pharmacies hurting cancer patients; colon cancer drugs cost twice in U.S. vs Canada

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Antibiotic shortages putting patients at risk; EMA fears staff losses as HQ move nears

By Ed Silverman

Insys Therapeutics headquarters
Pharmalot

Another Insys sales rep pleads guilty to bribing docs for writing Subsys prescriptions

By Ed Silverman

Pharmalot
Pharmalot

South Africa suggests overhauling patent policies to widen access to medicines

By Ed Silverman

Pharmalot

Pharmalittle: Trump predicts ‘massive’ price cuts soon; Gilead will advertise its HIV prevention pill

By Ed Silverman

Pharmalot

Sanofi’s internal memo after a subpoena illustrates concerns over MS drug marketing

By Ed Silverman

Pharmalot

Pharmalittle: Biogen escapes a compulsory license; could Ambien cause racist tweeting?

By Ed Silverman

Valeant Addyi
Pharmalot

The Addyi female libido pill has fewer restrictions in Canada. Is the U.S. next?

By Ed Silverman

Pharmalot

Pharmalittle: Did White House official violate ethics rules? Purdue execs knew about OxyContin abuse

By Ed Silverman

Celgene
Pharmalot

Investors’ ‘negative’ views on Celgene may be ‘warranted,’ analyst says

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Mylan pressures Pfizer to fix EpiPen production problems; AstraZeneca cancer drug hits goal

By Ed Silverman

Alex Brandon/AP
Pharmalot

In a setback to the FTC, a judge dismisses antitrust allegations against Impax Labs

By Ed Silverman

Pharmalot

Pfizer agrees to pay nearly $24M for illegally using a charity to pay kickbacks to Medicare patients

By Ed Silverman

Pharmalot

Pharmalittle: A battered Celgene does a big stock buyback; Senate committee to vote on pharmacy gag clause bill

By Ed Silverman

Pharmalot

Spending on cancer drugs in the U.S. has doubled in the last five years, and will double again

By Ed Silverman

Pharmalot

Solicitor general urges Supreme Court to review Merck case about warnings

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy